Abstract:Primary biliary cholangitis (PBC) is an archetypal autoimmune disease. Chronic lymphocytic cholangitis is associated with interface hepatitis, ductopenia, cholestasis, and progressive biliary fibrosis. People living with PBC are frequently symptomatic, experiencing a quality-of-life burden dominated by fatigue, itch, abdominal pain, and sicca complex. Although the female predominance, specific serum autoantibodies, immune-mediated cellular injury, as well as genetic (HLA and non-HLA) risk factors, identify PBC as autoimmune, to date treatment has focused on cholestatic consequences. Biliary epithelial homeostasis is abnormal and contributes to disease. The impact of cholangiocyte senescence, apoptosis, and impaired bicarbonate secretion enhances chronic inflammation and bile acid retention. First-line therapy is a non-specific anti-cholestatic agent, ursodeoxycholic acid. For those with residual cholestasis biochemically, obeticholic acid is introduced, and this semisynthetic farnesoid X receptor agonist adds choleretic, anti-fibrotic, and anti-inflammatory activity. Future PBC licensed therapy will likely include peroxisome proliferator activated receptor (PPAR) pathway agonists, including specific PPAR-delta agonism (seladelpar), as well as elafibrinor and saroglitazar (both with broader PPAR agonism). These agents dovetail the clinical and trial experience for off-label bezafibrate and fenofibrate use. Symptom management is essential, and encouragingly, PPAR agonists reduce itch; IBAT inhibition (eg, linerixibat) also appears promising for pruritus. For those where liver fibrosis is the target, NOX inhibition is being evaluated. Earlier stage therapies in development include therapy to impact immunoregulation in patients, as well other approaches to treating pruritus (eg, antagonists of MrgprX4). Collectively the PBC therapeutic landscape is exciting. Therapy goals are increasingly proactive and individualized and aspire to rapidly achieve normal serum tests and quality of life with prevention of end-stage liver disease.

S2711 Primary Biliary Cholangitis: A Peculiar Presentation

Clinical Analysis of Primary Biliary Cirrhosis: a Report of 31 Cases

Chemokine (C-X-C motif) ligand 13 promotes intrahepatic chemokine (C-X-C motif) receptor 5+ lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis.

Primary biliary cirrhosis:an analysis of 76 cases

[Primary biliary cholangitis. Experience in 179 patients]

[Clinical and Pathological Characteristics of Primary Biliary Cirrhosis].

Clonal Characteristics of Circulating B Lymphocyte Repertoire in Primary Biliary Cholangitis

Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis

A case of primary biliary cholangitis – diagnostic and treatment approaches

Precirrhotic Primary Biliary Cholangitis with Portal Hypertension: Bile Duct Injury Correlate

S72 Diagnostic Value of Anti-Mitochondrial Antibodies (AMA), Anti-M2, Anti-sp100, and Anti-gp210 in Primary Biliary Cholangitis (PBC)

New Treatment Paradigms in Primary Biliary Cholangitis

Analysis of Autoantibodies against Promyelocytic Leukemia Nuclear Body Components and Biochemical Parameters in Sera of Patients with Primary Biliary Cholangitis

Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.

Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis

Histological diagnosis of primary biliary cholangitis in one patient without cholestasis alterations: a case report that escaped guidelines

CD45ROhighCD57+CD8high T Cells in Primary Biliary Cirrhosis (101.4)

Current Landscape and Evolving Therapies for Primary Biliary Cholangitis

Clinical and Pathology Analysis of Patients with Primary Biliary Cirrhosis

CD45ROhighCD57+CD8high T cells in primary biliary cirrhosis

Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid